Target- |
MechanismNatural killer cell replacements |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer: A Single-arm, Single-center, Exploratory Clinical Study
The goal of this type of clinical trial study is to evaluate the safety and efficacy of metabolic remodeling nature killer cells as neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer
100 Clinical Results associated with Anhui Kecheng Intelligent Health Technology Co., Ltd.
0 Patents (Medical) associated with Anhui Kecheng Intelligent Health Technology Co., Ltd.
100 Deals associated with Anhui Kecheng Intelligent Health Technology Co., Ltd.
100 Translational Medicine associated with Anhui Kecheng Intelligent Health Technology Co., Ltd.